Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.49 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2163180 | 0.78 | LMNA (0.59) | LMNAP2RX7ALDH1A1KMT2AMEN1 | |
| SCHEMBL4408444 | 0.78 | LMNA (0.59) | LMNAP2RX7ALDH1A1KMT2AMEN1 | |
| SCHEMBL96819 | 0.78 | ALDH1A1 (0.57) | LMNAP2RX7ALDH1A1KMT2AMEN1 | |
| SCHEMBL2583045 | 0.78 | TSHR (0.44) | LMNAP2RX7ALDH1A1KMT2ATSHR | |
| SCHEMBL4631721 | 0.78 | ALDH1A1 (0.53) | LMNAALDH1A1TSHR | |
| SCHEMBL3261613 | 0.77 | LMNA (0.57) | LMNAP2RX7ALDH1A1KMT2AMEN1 | |
| SCHEMBL994214 | 0.77 | LMNA (0.57) | LMNAP2RX7ALDH1A1KMT2AMEN1 | |
| SCHEMBL3035928 | 0.77 | LMNA (0.62) | LMNAP2RX7ALDH1A1KMT2AMEN1 | |
| SCHEMBL950306 | 0.77 | LMNA (0.57) | LMNAP2RX7ALDH1A1KMT2AMEN1 | |
| SCHEMBL1318724 | 0.77 | LMNA (0.57) | LMNAP2RX7ALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306397-A1 | Method for the production of substituted azoles | LANXESS DEUTSCHLAND GMBH (DE) | 2009-12-10 | — | — | US | disclosed |
| EP-1891025-A1 | METHOD FOR THE PRODUCTION OF SUBSTITUTED AZOLES | Lanxess Deutschland GmbH (DE) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006131228-A1 | METHOD FOR THE PRODUCTION OF SUBSTITUTED AZOLES | LANXESS DEUTSCHLAND GMBH (DE) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306397-A1 | Method for the production of substituted azoles | CYP11B1, CYP11B2, CYP4F11 | LMNA 3460/4885P2RX7 3267/4885ALDH1A1 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.